- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00155064
Kallikrein-kinin (KKS) and Renin-angiotensin-aldosterone System (RAAS) in Primary Aldosteronism
The tissue kallikrein-kinin (KKS) and renin-angiotension-aldosterone system (RAAS) had been implicated in regulating blood pressure and electrolyte homeostasis. Both of the KKS and RAAS may work coordinately to regulate salt metabolism, local blood flow. Thus, we conducted this study to elucidate, first, whether some alterations in components of the kallikrein-kinin system could do effect on aldosterone secretion.
Previous study has shown the post captopril plasma aldosterone concentration (PAC)/ plasma rennin activity (PRA) ration (ARR) was a reliable method for diagnosis of primary aldosteronism (PA). The ARR change by angiotensin II receptor blockade was reported to be significantly higher than that by ACE inhibitor. This study assessed whether angiotensin II receptor blockade offers any additional advantage in the diagnosis of PA. Clinically we evaluated the sensitivity and specificity of captopril (angiotensin-converting enzyme inhibition) and losartan (angiotensin II type 1 receptor blocker) test in PA patient. This interaction mechanism, in term, could further explain the interaction of KKS and RAAS.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Hypertension affects 20% to 25% of adult population. Most patients are diagnosed as having essential or primary hypertension. Up to 10% to 15 % have an identifiable cause and many of those have an adrenal basis [Miroslava H. et al., 2002]. The tissue kallikrein-kinin (KKS) and renin-angiotension-aldosterone system (RAAS) had been implicated in regulating blood pressure and electrolyte homeostasis. Recent studies in humans indicate that the vasodilator tissue KKS, the counterpart of the tissue RAAS, is also expressed in the adrenal gland. The adrenal gland regulates sodium and water excretion and reabsorption through the release of aldosterone and corticosterone. Previous study reveals an anatomical linkage between the tissue KKS and sodium and water metabolism. Both of the KKS and RAAS may work coordinately to regulate salt metabolism, local blood flow. In contrast, although many investigators have supported the notion that Ang II and BK physiologically antagonize each other's effects on blood pressure, there are many instances where the two peptides exert common actions. For example, the Bradykinin also stimulates aldosterone release from adrenocortical cells through B2 receptors. Furthermore, the AT1 receptor and the bradykinin (B2) receptor form stable heterodimers, the two major signaling proteins triggered by AT1. In vitro studies (Margolius 1995) have shown that kallikrein acts as a prorenin-activating enzyme, and that tissue kallikrein can generate angiotensin II.
However, the interactions between both systems are complex and not always simply antagonistic. The interactions of the two systems on aldosterone secretion are not examined Thus, we conducted this study to elucidate, first, whether some alterations in components of the kallikrein-kinin system could do effect on aldosterone secretion.
Our study provides evidence that bradykinin contributes substantially to the aldosterone secretion with or without the effects of angiotensin. The data also could confirm whether ATR2-Bradykinin-B2-aldosterone really works. We want to realize the expression of angiotensin and bradykinin in the adrenal gland and hypertension related to these systems.
Previous study has showed the post captopril plasma aldosterone concentration (PAC)/ plasma rennin activity (PRA) ration (ARR) was a reliable method for diagnosis of primary aldosteronism (PA). The ARR change by angiotensin II receptor blockade was reported to be significantly higher than that by ACE inhibitor. This study assessed whether angiotensin II receptor blockade offers any additional advantage in the diagnosis of PA. Clinically we evaluated the sensitivity and specificity of captopril (angiotensin-converting enzyme inhibition) and losartan (angiotensin II type 1 receptor blocker) test in PA patient. This interaction mechanism, in term, could further explain the interaction of KKS and RAAS.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Taipei, Taiwan
- National Taiwan University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients with hypertension admitted for the diagnosis of primary aldosteronism
Exclusion Criteria:
Pregnant or lactating women. (Pre-menopause women, capable of bearing children will undergo pregnancy test), hypertension without discontinuous b-blocker, ACEI or ARB for more than 10 days.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Diagnosis of primary aldosteronism
|
Secondary Outcome Measures
Outcome Measure |
---|
Subgroup analysis of primary aldosteronism
|
Collaborators and Investigators
Investigators
- Study Chair: Kwan-Dun Wu, MD, PhD, National Taiwan University Hospital
- Study Director: Vin-Cent Wu, MD, National Taiwan University Hospital
Publications and helpful links
General Publications
- Agharazii M, Douville P, Grose JH, Lebel M. Captopril suppression versus salt loading in confirming primary aldosteronism. Hypertension. 2001 Jun;37(6):1440-3. doi: 10.1161/01.hyp.37.6.1440.
- Dendorfer A, Wolfrum S, Dominiak P. Pharmacology and cardiovascular implications of the kinin-kallikrein system. Jpn J Pharmacol. 1999 Apr;79(4):403-26. doi: 10.1254/jjp.79.403.
- Hesse B, Rasmussen S, Lund JO, Christensen P, Damkjaer Nielsen M. Urinary excretion of kallikrein before and after operation for aldosterone-producing adenoma. Acta Med Scand. 1985;217(5):501-5. doi: 10.1111/j.0954-6820.1985.tb03253.x.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Endocrine System Diseases
- Adrenocortical Hyperfunction
- Adrenal Gland Diseases
- Hyperaldosteronism
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Enzyme Inhibitors
- Protease Inhibitors
- Angiotensin II Type 1 Receptor Blockers
- Angiotensin Receptor Antagonists
- Angiotensin-Converting Enzyme Inhibitors
- Losartan
- Captopril
Other Study ID Numbers
- 9361700632
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperaldosteronism
-
Haukeland University HospitalCompleted
-
University of Erlangen-Nürnberg Medical SchoolRecruitingPrimary Hyperaldosteronism | Electrolyte DisturbanceGermany
-
University Hospital, CaenRecruiting
-
Assistance Publique - Hôpitaux de ParisCompletedHealthy | Essential Hypertension | Primary Hyperaldosteronism | Secondary HyperaldosteronismFrance
-
Radboud University Medical CenterCompletedPrimary Aldosteronism | Primary HyperaldosteronismNetherlands
-
NovartisCompletedPrimary HyperaldosteronismFrance
-
University College, LondonUniversity College London Hospitals; Cambridge University Hospitals NHS Foundation... and other collaboratorsCompletedPrimary Hyperaldosteronism | Primary Hyperaldosteronism Due to Adrenal AdenomaUnited Kingdom
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...RecruitingPrimary Aldosteronism | Aldosterone-Producing Adenoma | Idiopathic HyperaldosteronismChina
-
Qifu LiFu Wai Hospital, Beijing, ChinaCompletedHyperaldosteronism; Primary | Hypertension SecondaryChina
-
Imperial College LondonDr Katrina Ohla, Institute of Neuroscience and Medicine, Julich, GermanyUnknownHypertension | Hyperaldosteronism; Primary | Salt; Excess | Appetite DisordersUnited Kingdom
Clinical Trials on captopril, Losartan (drug)
-
Odense University HospitalUniversity of Southern Denmark; Lundbeck Foundation; Else Poulsen MindelegatUnknown
-
Rigshospitalet, DenmarkUnknown
-
Radiation Therapy Oncology GroupNational Cancer Institute (NCI); NRG OncologyTerminatedLung Cancer | Pulmonary Complications | Radiation FibrosisUnited States
-
University of CalgaryDr. Sandra DumanskiRecruitingHormone TherapyCanada
-
National Taiwan University HospitalNovartisUnknown
-
Chongqing Medical UniversityChinese PLA General Hospital; Tianjin Medical University General Hospital; Chinese...Recruiting
-
Baker Heart and Diabetes InstituteWithdrawn
-
Instituto de Cardiologia do Rio Grande do SulCompleted
-
Assistance Publique - Hôpitaux de ParisUnknownCOVID-19 | Coronavirus Infection | PneumoniaFrance